Menu Search
Equities

Prestige Consumer Healthcare Inc

PBH:DEU

Prestige Consumer Healthcare Inc

Actions
  • Price (EUR)65.50
  • Today's Change1.00 / 1.55%
  • Shares traded0.00
  • 1 Year change+16.96%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. The Company operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands include Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others.

  • Revenue in USD (TTM)1.13bn
  • Net income in USD-80.67m
  • Incorporated2004
  • Employees560.00
  • Location
    Prestige Consumer Healthcare Inc660 White Plains RdTARRYTOWN 10591-5139United StatesUSA
  • Phone+1 (914) 524-6800
  • Fax+1 (302) 674-5266
  • Websitehttps://www.prestigebrands.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.